Holds one active US DMF and one valid CEP for terlipressin, filing since 2019. Its 2025 FDA inspection closed as VAI.
Holds one valid CEP for terlipressin, filing since 2022. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 10 markets.
Holds one valid CEP for terlipressin, filing since 2021. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 3 markets.
Registered with SFDA (Saudi Arabia) for terlipressin. Its 2023 FDA inspection closed as VAI, and its GMP is recognised in 1 market.
Registered with DAV (Vietnam) for terlipressin. Its GMP is recognised in 1 market.
Registered with DAV (Vietnam) for terlipressin. Its GMP is recognised in 1 market.
The names are listed below. Ask Fred about the filings, inspection history and GMP certificates on record for each manufacturer.
Chat with Fred, your AI analystContract manufacturers make to order rather than holding their own filing for this molecule.
The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Every factor appears on the card it produced. Read the full method.
Ask Fred which manufacturers are on record for terlipressin and what filings they hold.
Chat with Fred, your AI analyst